Goede, Valentin, Klein, Christian ORCID: 0000-0001-7594-7280 and Stilgenbauer, Stephan (2015). Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncol. Res. Treat., 38 (4). S. 185 - 193. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Abstract

Obinutuzumab (GA101) is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the Fc gamma RIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. Preclinical data demonstrated more efficient B-cell depletion in whole blood and superior antitumor activity in xenograft models of obinutuzumab as compared to the type I CD20 antibody rituximab. In previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, obinutuzumab plus chlorambucil increased response rates and prolonged progression-free survival compared with rituximab plus chlorambucil. Obinutuzumab had an acceptable and manageable safety profile, with infusion-related reactions during the first infusion as the most common adverse event. Further phase I/II clinical trials have also shown promising activity in other CD20-positive B-cell non-Hodgkin's lymphomas (NHL). Therefore, several clinical studies are planned or ongoing to investigate obinutuzumab with different combination partners in both untreated and relapsed/refractory patients with different B-cell NHL entities, which in addition to CLL include diffuse large B-cell lymphoma and follicular lymphoma.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Goede, ValentinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klein, ChristianUNSPECIFIEDorcid.org/0000-0001-7594-7280UNSPECIFIED
Stilgenbauer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-408057
DOI: 10.1159/000381524
Journal or Publication Title: Oncol. Res. Treat.
Volume: 38
Number: 4
Page Range: S. 185 - 193
Date: 2015
Publisher: KARGER
Place of Publication: BASEL
ISSN: 2296-5262
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTI-CD20 MONOCLONAL-ANTIBODY; CHEMOTHERAPY PLUS RITUXIMAB; CHOP; FC; PHAGOCYTOSIS; INDUCTION; TARGET; DEATH; TRIAL; CLLMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/40805

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item